Phase III trial results for semaglutide (EVOKE and EVOKE Plus) are anticipated in September 2025, investigating its potential to slow cognitive decline in Alzheimer's patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.